奎平可以竞争性地抑制NCB20神经母细胞细胞中的5-HT3受体介导电流
Yong Soo Park1, Gyu Min Kim2, Ho Jun Sung2
1Department of Anatomy, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
概括
奎平通过改变离子通道动力学来竞争性抑制5-基三胺3型 (5-HT3) 受体. 这项研究揭示了quetiapine的存在.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 5西胺3型 (5-HT3) 受体对突触传播至关重要,并与神经精神疾病有关.
- 了解奎平与5-HT3受体的相互作用是其治疗应用的关键.
研究的目的:
- 阐明奎平对5-HT3受体介导电流的抑制机制.
- 为了研究奎平对5-HT3受体离子通道动力学和对抗性的影响.
主要方法:
- 在NCB20神经母细胞瘤细胞中全细胞补丁记录.
- 分析了5-HT度-反应曲线和奎平的IC50值.
- 研究受体动力学,包括停活,脱敏和恢复.
主要成果:
- 奎平具有竞争性抑制5-HT3受体的作用,由5-HT度-反应曲线的向右转移表明.
- 奎蒂亚平的抑制功效依赖于度和条件,在预治疗后有效性增加.
- 奎胺通过加速失活和脱敏,并延长脱敏后的恢复,改变受体动态.
结论:
- 奎平作为5-HT3受体的竞争性对手,稳定其在非导电状态.
- 这些发现提供了关于奎平的作用机制和调节血清路径的潜力的见解.
更多相关视频
10:20Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b
Published on: November 11, 2016
8.5K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174